Zhuang R, Ge X, Han L, et al
Following the massive success of WEGOVY (semaglutide 2.4 mg), the company is evaluating semaglutide 7.2 mg in phase III obesity drug clinical trials
In the SUSTAIN clinical trials, semaglutide OW achieved superior glycemic control and weight loss compared with several other classes of anti-diabetes medications (ADMs) [14,15,16,17,18], including canagliflozin, an SGLT2i [19]
After pinpointing specific aspects of sleep that require improvement, Huberman recommends that individuals experiment with individual sleep-supporting supplements for at least a week, provided there are no adverse side effects
Long-Term Solution With proper monitoring, spironolactone can be used safely long-term, providing ongoing protection against androgenic hair loss for years
The PA can be completed via CoverMyMeds